Streetbeat News

CMND

Clearmind Medicine Inc.

https://www.clearmindmedicine.com

Industry

Biotechnology

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Open

1.40

Mkt cap

5.7M

Volume

41K

High

1.40

P/E Ratio

-1.14

52-wk high

6.80

Low

1.36

Div yield

N/A

52-wk low

0.92

Clearmind Medicine Inc. (CMND) has announced a registered direct and private placement offering to raise approximately $2.4 million. The offering includes the sale of 1,500,000 Common Units or Pre-Funded Units, each comprising one Common Share or Pre-Funded Warrant, and one PIPE Common Warrant, with an exercise price of $1.60. The proceeds are intended for general corporate purposes and working capital. Aegis Capital Corp. is the Exclusive Placement Agent, and various legal firms are providing counsel. The offering is not available to Canadians and is expected to close around January 16, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 2:29 pm

Richardson Electronics, Ltd. (NASDAQ:RELL) shares dropped by 13.2% in pre-market trading after reporting a Q2 loss of 13 cents per share versus the expected earnings of 1 cent per share, and sales of $44.13 million against the anticipated $52.00 million. Other stocks experienced pre-market movements, with some gaining due to various factors such as Bitcoin price strength, asset sales, and acquisition announcements, while others fell due to patent grants, regulatory updates, and previous day movements.

Portfolio Pulse from Avi Kapoor

January 11, 2024 | 12:51 pm

U.S. stocks traded higher with the Dow Jones gaining over 100 points. Communication services shares rose by 1.1%, while energy shares fell by 1.3%. U.S. wholesale inventories declined by 0.2% in November. Clearmind Medicine Inc. (CMND) shares surged 44% after an FDA meeting. Amarin Corporation plc (AMRN) shares jumped 28% on Q4 results and a share repurchase program. Nauticus Robotics, Inc. (KITT) gained 87% after securing funding and appointing a new interim CEO. DocGo Inc. (DCGO) shares fell 35% following a negative report by Fuzzy Panda Research. Aclaris Therapeutics, Inc. (ACRS) shares dropped 24% after a Phase 2B study failed to meet the primary efficacy endpoint. Aehr Test Systems (AEHR) fell 15% after lowering its full-year revenue guidance. Crude oil fell 1.1% to $71.46, and gold slightly declined.

Portfolio Pulse from Avi Kapoor

January 10, 2024 | 7:16 pm

WD-40 Company (NASDAQ:WDFC) shares surged over 17% after reporting Q1 earnings of $1.28 per share, surpassing estimates of $1.05 per share, and sales of $140.42 million, above the expected $134.37 million. Other stocks experienced significant movements in Wednesday's mid-day session, with various companies reporting funding, FDA interactions, earnings, and other corporate updates.

Portfolio Pulse from Avi Kapoor

January 10, 2024 | 6:06 pm

Clearmind Medicine Inc (NASDAQ:CMND) stock soared after announcing the completion of a Type A meeting with the FDA regarding its clinical trial for CMND-100, a compound for treating Alcohol Use Disorder with psychedelic-based therapy. The active ingredient, MEAI, is reported to reduce alcohol consumption desires while providing a euphoric experience. The company aims to resubmit its IND for CMND-100 and bring new treatment options for AUD.

Portfolio Pulse from Adam Eckert

January 10, 2024 | 2:57 pm

Clearmind Medicine's stock price has increased following the announcement of a completed Type A meeting with the U.S. Food and Drug Administration.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 2:43 pm

TG Therapeutics projects Q1 BRIUMVI U.S. net product revenue to be between $41M and $46M, with an anticipated FY24 revenue of $220M to $260M. Clearmind Medicine has completed a Type A meeting with the FDA for its MEAI-based compound, CMND-100, aimed at treating Alcohol Use Disorder. SEALSQ has launched an innovative semiconductor provisioning service that promises to reduce lead times to just 4 weeks.

Portfolio Pulse from ryanfaloona@benzinga.com

January 10, 2024 | 1:44 pm

Clearmind Medicine has completed a Type A meeting with the FDA regarding the clinical trial of its proprietary MEAI-based compound, CMND-100, aimed at treating Alcohol Use Disorder.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:21 pm

SciSparc and Clearmind Medicine have successfully collaborated throughout 2023 and are planning to enhance a variety of psychedelic-based treatments. Their joint efforts aim to innovate and improve therapeutic options in the field of psychedelic medicine.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:21 pm

President Biden signed the 2024 NDAA, which includes funding for clinical trials with psychedelics for active military members. Robert F. Kennedy Jr. expressed support for psychedelics in mental health treatment. Incannex Healthcare (NASDAQ:IXHL) is set to open Australia's first dedicated psychedelic-assisted therapy clinic. Psychedelics stocks showed varied performance, with COMPASS Pathways (NASDAQ:CMPS) closing at $8.75, and AdvisorShares Psychedelics ETF (NYSE:PSIL) closing at $1.42.

Portfolio Pulse from Lara Goldstein

December 27, 2023 | 3:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.